• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    7/28/23 9:05:59 AM ET
    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ASXC alert in real time by email

    Gainers

    • Reata Pharmaceuticals (NASDAQ:RETA) shares rose 52.2% to $165.24 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 billion.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares rose 35.7% to $7.26. The company's market cap stands at $7.4 million.
    • SIGA Technologies (NASDAQ:SIGA) stock increased by 26.74% to $6.45. The company's market cap stands at $459.7 million.
    • Homology Medicines (NASDAQ:FIXX) shares moved upwards by 22.34% to $1.15. The market value of their outstanding shares is at $66.4 million.
    • Creative Medical Tech (NASDAQ:CELZ) shares rose 17.43% to $6.6. The market value of their outstanding shares is at $9.2 million.
    • Asensus Surgical (AMEX:ASXC) stock increased by 11.63% to $0.33. The market value of their outstanding shares is at $80.1 million.

    Losers

    • Tonix Pharmaceuticals (NASDAQ:TNXP) shares decreased by 42.7% to $1.02 during Friday's pre-market session. The company's market cap stands at $10.5 million.
    • Bellerophon Therapeutics (NASDAQ:BLPH) shares declined by 15.8% to $0.38. The company's market cap stands at $4.0 million.
    • Femasys (NASDAQ:FEMY) stock decreased by 15.47% to $0.71. The market value of their outstanding shares is at $10.7 million.
    • Telesis Bio (NASDAQ:TBIO) shares fell 12.35% to $1.42. The market value of their outstanding shares is at $42.2 million.
    • Mallinckrodt (AMEX:MNK) stock fell 10.55% to $1.45. The company's market cap stands at $19.0 million.
    • Titan Pharma (NASDAQ:TTNP) shares decreased by 10.0% to $0.53. The market value of their outstanding shares is at $7.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASXC
    $BJDX
    $BLPH
    $CELZ

    CompanyDatePrice TargetRatingAnalyst
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Asensus Surgical Inc.
    $ASXC
    11/16/2023Overweight → Neutral
    Cantor Fitzgerald
    Homology Medicines Inc.
    $FIXX
    7/28/2023$9.00 → $1.50Outperform → Neutral
    Robert W. Baird
    Reata Pharmaceuticals Inc.
    $RETA
    7/6/2023$140.00Outperform
    TD Cowen
    Reata Pharmaceuticals Inc.
    $RETA
    6/12/2023$80.00 → $115.00Market Perform → Outperform
    SVB Securities
    Reata Pharmaceuticals Inc.
    $RETA
    10/19/2022$75.00Buy
    Guggenheim
    Asensus Surgical Inc.
    $ASXC
    9/8/2022$1.50Overweight
    Cantor Fitzgerald
    Asensus Surgical Inc.
    $ASXC
    9/8/2022$1.50Buy
    Stifel
    More analyst ratings

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

    BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026: TD Cowen 46th Annual Healthcare ConferenceCompany PresentationPresenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate: Wednesday March 4, 2026Place: Boston Marriott Copley PlaceTime: 11:10 AM – 11:40 AM ETRoom: MIT, 3rd Floor Barclays 28th Annual Healthcare Conference Company ParticipationManagement will be available for 1x1 meetings, March 10 - 12, a

    2/25/26 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

    -- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code covering the use of FemaSeed for intratubal insemination (ITI), a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT co

    2/23/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

    ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share. The Company notes that several recent Schedule 13G filings made by investors

    2/20/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:37:51 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Elefant Dov

    4 - FEMASYS INC (0001339005) (Issuer)

    2/20/26 5:32:25 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Sipos Jeremy Alexander

    4 - FEMASYS INC (0001339005) (Issuer)

    2/17/26 5:47:34 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Asensus Surgical downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral

    11/16/23 7:11:26 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care

    Homology Medicines downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously

    7/28/23 7:17:02 AM ET
    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    SEC Filings

    View All

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/20/26 9:54:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.

    SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    2/18/26 4:48:34 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/17/26 9:54:58 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

    Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

    2/28/23 5:14:09 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Taylor Carolyn E. bought $15,061 worth of shares (418 units at $36.03) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/21/25 5:22:56 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Treco James bought $9,000 worth of shares (250 units at $36.00) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/20/25 4:15:15 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lederman Seth bought $86,200 worth of shares (4,000 units at $21.55), increasing direct ownership by 80,000% to 4,005 units (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    5/15/25 5:08:40 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Leadership Updates

    Live Leadership Updates

    View All

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

    Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights. "Following U.S. Food a

    11/10/25 4:15:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

    Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years US Launch of Tonmya expected in the fourth quarter of 2025 CHATHAM, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the appointment of Ganesh Kamath as Head of Market Access

    9/30/25 8:30:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASXC
    $BJDX
    $BLPH
    $CELZ
    Financials

    Live finance-specific insights

    View All

    SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025

    NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. "We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer. " As we look forward to the remainder of 2025 and prepare for 2026, we are focused on building upon our long track record as a successful partner with the U.S. Government and international governments to secure new procurement contracts and orders that wi

    11/6/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

    NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-

    10/30/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administratio

    8/15/25 3:44:52 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care